US Stock Insider Trading | Zentalis disclosed two insider trading transactions on February 4

2026-02-19 04:38:20

On February 4, 2026, Zentalis (ZNTL) disclosed two insider trading transactions. Executive Vultaggio Vincent sold 2,540 shares on February 3, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share (USD)	Total Amount (USD)
February 4, 2026	Executive	Vultaggio Vincent	February 3, 2026	Sell	556	2.52	1,398.34
February 4, 2026	Executive	Vultaggio Vincent	February 2, 2026	Sell	2,540	2.55	6,477.00
January 8, 2026	Shareholder with >10% stake	WALTERS GROUP	December 31, 2025	Buy	6.46 million	1.20	7.752 million
December 15, 2025	Shareholder with >10% stake	Matrix Capital Management Company, LP	December 15, 2025	Sell	7.50 million	1.33	9.975 million
April 30, 2025	Director	Myers Scott Dunseth	April 30, 2025	Buy	21,000	1.40	14,000
February 12, 2025	Executive	Bruns Ingmar	February 6, 2025	Buy	20,000	2.28	45,700
February 5, 2025	Executive	Paul Andrea	February 3, 2025	Sell	13,200	1.71	22,600
February 5, 2025	Executive	Vultaggio Vincent	February 3, 2025	Sell	2,615	1.71	4,475.57
February 5, 2025	Executive	Lackner Mark	February 3, 2025	Sell	14,000	1.71	24,600
January 31, 2025	Director	Skvarka Jan	January 31, 2025	Buy	60,000	1.72	103,400

[Company Information]

Zentalis Pharmaceuticals, Inc. was incorporated in Delaware on December 23, 2014, as Zeno Pharmaceuticals, Inc. Zentalis Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company dedicated to discovering and developing novel small molecule therapies targeting fundamental biological pathways in cancer.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.